JP2023550832A5 - - Google Patents
Info
- Publication number
- JP2023550832A5 JP2023550832A5 JP2023532306A JP2023532306A JP2023550832A5 JP 2023550832 A5 JP2023550832 A5 JP 2023550832A5 JP 2023532306 A JP2023532306 A JP 2023532306A JP 2023532306 A JP2023532306 A JP 2023532306A JP 2023550832 A5 JP2023550832 A5 JP 2023550832A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- variable region
- chain variable
- seq
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020132392 | 2020-11-27 | ||
| CNPCT/CN2020/132392 | 2020-11-27 | ||
| CN202111396829.4 | 2021-11-23 | ||
| CN202111396829 | 2021-11-23 | ||
| PCT/CN2021/133083 WO2022111576A1 (en) | 2020-11-27 | 2021-11-25 | Novel conjugate molecules targeting cd39 and tgfβeta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550832A JP2023550832A (ja) | 2023-12-05 |
| JP2023550832A5 true JP2023550832A5 (https=) | 2024-11-21 |
Family
ID=81755308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532306A Pending JP2023550832A (ja) | 2020-11-27 | 2021-11-25 | ＣＤ３９およびＴＧＦβを標的とする新規のコンジュゲート分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230416394A1 (https=) |
| EP (1) | EP4251650A4 (https=) |
| JP (1) | JP2023550832A (https=) |
| KR (1) | KR20230113752A (https=) |
| CN (1) | CN115052894A (https=) |
| AU (1) | AU2021389989A1 (https=) |
| CA (1) | CA3202988A1 (https=) |
| TW (1) | TW202237651A (https=) |
| WO (1) | WO2022111576A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| MX2024010646A (es) | 2022-03-03 | 2024-09-19 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos. |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
| EP4669350A1 (en) | 2023-02-24 | 2025-12-31 | Institut National de la Santé et de la Recherche Médicale | ENDOMETRIOSIS TREATMENT METHODS |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| MY202018A (en) * | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019173692A2 (en) * | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| KR20230020023A (ko) * | 2018-03-14 | 2023-02-09 | 서피스 온콜로지, 인크. | Cd39에 결합하는 항체 및 이의 용도 |
| AU2019301070B2 (en) * | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
| JP7727387B2 (ja) * | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
-
2021
- 2021-11-25 AU AU2021389989A patent/AU2021389989A1/en not_active Abandoned
- 2021-11-25 JP JP2023532306A patent/JP2023550832A/ja active Pending
- 2021-11-25 CA CA3202988A patent/CA3202988A1/en active Pending
- 2021-11-25 US US18/254,606 patent/US20230416394A1/en active Pending
- 2021-11-25 KR KR1020237018338A patent/KR20230113752A/ko not_active Withdrawn
- 2021-11-25 EP EP21897076.2A patent/EP4251650A4/en active Pending
- 2021-11-25 WO PCT/CN2021/133083 patent/WO2022111576A1/en not_active Ceased
- 2021-11-25 CN CN202180008687.1A patent/CN115052894A/zh active Pending
- 2021-11-26 TW TW110144242A patent/TW202237651A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023550832A5 (https=) | ||
| AU2020415159B2 (en) | Anti-LILRB1 antibody and uses thereof | |
| JP2022515318A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021524278A (ja) | 抗メソテリン抗体 | |
| WO2019222428A1 (en) | Composition of bispecific antibodies and method of use thereof | |
| JP2020510422A5 (https=) | ||
| CN115551889A (zh) | 抗cd73抗体及其用途 | |
| JP2022507679A (ja) | Ｈｅｒ２／ｐｄ１二重特異性抗体 | |
| CN110831973A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN110799540A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022534297A (ja) | 抗ｂ７－ｈ３抗体 | |
| JP7392145B2 (ja) | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム | |
| JP2024544520A5 (https=) | ||
| JP2022527173A5 (https=) | ||
| TW202221035A (zh) | 抗ilt2抗體及其用途 | |
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CN120731229A (zh) | FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分 | |
| CN110662764B (zh) | 抗程序性死亡配体1(pd-l1)抗体及其治疗用途 | |
| EP4299594A1 (en) | Gucy2c binding polypeptide and uses thereof | |
| JP2024527043A5 (https=) | ||
| CN117677635A (zh) | 新颖pd-1结合域 | |
| WO2026046336A1 (zh) | Trop2/MUC1结合分子及医药用途 | |
| Wang et al. | The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity |